Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Subunit protein vaccines: theoretical and practical considerations for HIV-1.

Cho MW.

Curr Mol Med. 2003 May;3(3):243-63. Review.

PMID:
12699361
2.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6. Epub 2006 Dec 24.

PMID:
17187074
3.

Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination.

Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, Overend P, van Wely C, Thomsen LL, Wahren B, Voss G, Heeney JL.

J Gen Virol. 2008 Feb;89(Pt 2):540-53. doi: 10.1099/vir.0.83384-0.

PMID:
18198386
4.

Recent advances in the development of HIV-1 Tat-based vaccines.

Caputo A, Gavioli R, Ensoli B.

Curr HIV Res. 2004 Oct;2(4):357-76. Review.

PMID:
15544457
5.

Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.

Devadas K, Boykins RA, Hewlett IK, Wood OL, Clouse KA, Yamada KM, Dhawan S.

Peptides. 2007 Mar;28(3):496-504. Epub 2006 Dec 22.

PMID:
17188401
6.

The basis for HIV immunotherapeutic vaccines.

Peters BS.

Vaccine. 2001 Dec 12;20(5-6):688-705. Review.

PMID:
11738732
7.

Ability to generate synthetic peptides that immunologically mimic HIV-1 tat regulatory protein.

Biquard JM, M'Bika JP, Krsmanovic V, Achour A.

AIDS. 2003 Sep 5;17(13):2001-2. No abstract available.

PMID:
12960840
8.

Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.

McBurney SP, Ross TM.

Curr Pharm Des. 2007;13(19):1957-64. Review.

PMID:
17627529
9.

Biological considerations in the development of a human immunodeficiency virus vaccine.

Nathanson N, Mathieson BJ.

J Infect Dis. 2000 Aug;182(2):579-89. Epub 2000 Jul 28. Review.

PMID:
10915092
10.

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.

Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.

Vaccine. 2007 Mar 1;25(11):2145-54. Epub 2006 Nov 13.

PMID:
17254672
11.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

12.

Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.

Belliard G, Hurtrel B, Moreau E, Lafont BA, Monceaux V, Roques B, Desgranges C, Aubertin AM, Le Grand R, Muller S.

Vaccine. 2005 Feb 3;23(11):1399-407.

PMID:
15661389
13.

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B.

Vaccine. 2008 Feb 26;26(9):1214-27. doi: 10.1016/j.vaccine.2007.12.030. Epub 2008 Jan 15.

PMID:
18243435
15.

Particle-based vaccines for HIV-1 infection.

Young KR, Ross TM.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):151-69. Review.

PMID:
12769792
16.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group..

J Infect Dis. 2004 Apr 1;189(7):1221-31. Epub 2004 Mar 15.

PMID:
15031791
17.

HIV vaccine development: lessons from the past and promise for the future.

Spearman P.

Curr HIV Res. 2003 Jan;1(1):101-20. Review.

PMID:
15043215
18.

Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.

Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.

Vaccine. 2004 Sep 9;22(27-28):3676-90.

PMID:
15315847
19.

Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.

Turbant S, Martinon F, Moine G, Le Grand R, Léonetti M.

Vaccine. 2009 Aug 27;27(39):5349-56. doi: 10.1016/j.vaccine.2009.06.083. Epub 2009 Jul 14.

PMID:
19607953
20.

Vaccines and vaccine strategies against HIV.

Stratov I, DeRose R, Purcell DF, Kent SJ.

Curr Drug Targets. 2004 Jan;5(1):71-88. Review.

PMID:
14738219

Supplemental Content

Support Center